Open AccessVesicular Stomatitis Virus-Based Epstein-Barr Virus Vaccines Elicit Strong Protective Immune Responses
Author(s) -
XiangWei Kong,
Xiao Zhang,
GuoLong Bu,
Hui-Qin Xu,
Yinfeng Kang,
Cong Sun,
QianYing Zhu,
Run-Bo Ma,
Zheng Liu,
YiXin Zeng,
MuSheng Zeng,
Zhu-Long Hu
Publication year - 2022
Publication title -
journal of virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.617
H-Index - 292
eISSN - 1070-6321
pISSN - 0022-538X
DOI - 10.1128/jvi.00336-22
Subject(s) - vesicular stomatitis virus , virology , biology , virus , immune system , antibody , neutralizing antibody , adjuvant , immunology
Epstein-Barr virus (EBV), one of the most common human viruses and the first identified human oncogenic virus, accounted for 265,000 cancer incident cases and 164,000 cancer deaths in 2017 as well as millions of nonmalignant disease cases. So far, no prophylactic vaccine is available to prevent EBV infection.